The Astellas Group is a leading, worldwide pharmaceutical company with a track record of success in developing and marketing pharmaceutical products with large markets. AVM's role is to provide its portfolio companies with access to asset of the Astellas Group to contribute to the rapid growth and success of emerging biotech companies in which we invest.

AVM offers many opportunities for emerging companies to tap into the Astellas Group's worldwide personnel networks, research centers, scientific expertise, production facilities and marketing operations. AVM portfolio companies are encouraged, but not mandated, to work with those resources of the Astellas Group most useful to them at particular points in their development, whether in research and development, clinical trials, production, marketing or administration. The availability of this comprehensive, first-class resource base can help emerging companies maximize their value while reducing, or more flexibly scheduling, expenditures on infrastructure.